BRIEF-Omeros Reaches Agreement With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy
January 03, 2018 at 07:14 AM EST
* OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |